NRG-BR001: A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases

NRG-BR001PowerPoint Presentation

Principal Investigator

Steven Chmura, MD

Primary Objective

To determine the recommended  SBRT dose for each of the metastatic locations being treated given the individual and overlapping fields when multiple metastases are treated with SBRT in a national clinical trials network setting

Patient Population

Oligometastases arising from the breast, lung or prostate; oligometastases defined as ≤ 4 distinct metastases visualized on standard imaging studies; all metastases not resected must be amenable to SBRT; local and regional disease treated per standard of care with no evidence of progression

Target Accrual



Activated August 4, 2014

Protocol Documents

The protocol and related documents are available at NRG-BR001

RT Credentialing and Treatment Planning Materials  

Click here to visit the IROC website for extensive information about benchmark case planning, credentialing, and treatment planning guidelines.

Copyright 2017 by NRG Oncology